DrugCite
Search

COMBIGAN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Combigan Adverse Events Reported to the FDA Over Time

How are Combigan adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Combigan, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Combigan is flagged as the suspect drug causing the adverse event.

Most Common Combigan Adverse Events Reported to the FDA

What are the most common Combigan adverse events reported to the FDA?

Ocular Hyperaemia
150 (4.92%)
Eye Irritation
141 (4.63%)
Eye Pruritus
94 (3.09%)
Eye Pain
92 (3.02%)
Dizziness
85 (2.79%)
Vision Blurred
71 (2.33%)
Dry Mouth
49 (1.61%)
Intraocular Pressure Increased
48 (1.58%)
Fatigue
47 (1.54%)
Headache
46 (1.51%)
Asthenia
43 (1.41%)
Show More Show More
Dyspnoea
43 (1.41%)
Eye Swelling
39 (1.28%)
Hypotension
39 (1.28%)
Erythema Of Eyelid
38 (1.25%)
Drug Ineffective
37 (1.21%)
Hypersensitivity
37 (1.21%)
Somnolence
35 (1.15%)
Lacrimation Increased
34 (1.12%)
Eyelid Oedema
32 (1.05%)
Erythema
26 (.85%)
Blood Pressure Decreased
25 (.82%)
Bradycardia
25 (.82%)
Visual Acuity Reduced
25 (.82%)
Eye Discharge
24 (.79%)
Muscular Weakness
22 (.72%)
Dry Eye
21 (.69%)
Foreign Body Sensation In Eyes
21 (.69%)
Pruritus
21 (.69%)
Conjunctivitis Allergic
19 (.62%)
Photophobia
17 (.56%)
Asthma
16 (.53%)
Iridocyclitis
16 (.53%)
Oedema Peripheral
16 (.53%)
Chest Discomfort
15 (.49%)
Hypertension
15 (.49%)
Iris Adhesions
15 (.49%)
Lethargy
15 (.49%)
Skin Exfoliation
15 (.49%)
Depression
14 (.46%)
Dry Skin
14 (.46%)
Eye Infection
14 (.46%)
Malaise
14 (.46%)
Visual Impairment
14 (.46%)
Vitreous Haemorrhage
14 (.46%)
Chest Pain
13 (.43%)
Confusional State
13 (.43%)
Corneal Deposits
13 (.43%)
Eye Inflammation
13 (.43%)
Eyelids Pruritus
13 (.43%)
Insomnia
13 (.43%)
Palpitations
13 (.43%)
Conjunctivitis
12 (.39%)
Cough
12 (.39%)
Blepharitis
11 (.36%)
Blood Pressure Increased
11 (.36%)
Burning Sensation
11 (.36%)
Drug Hypersensitivity
11 (.36%)
Eye Disorder
11 (.36%)
Eyelid Irritation
11 (.36%)
Eyelid Margin Crusting
11 (.36%)
Loss Of Consciousness
11 (.36%)
Ulcerative Keratitis
11 (.36%)
Corneal Disorder
10 (.33%)
Heart Rate Decreased
10 (.33%)
Mydriasis
10 (.33%)
Nephropathy Toxic
10 (.33%)
Rash
10 (.33%)
Swelling Face
10 (.33%)
Uveitis
10 (.33%)
Abnormal Sensation In Eye
9 (.3%)
Alopecia
9 (.3%)
Eyelid Ptosis
9 (.3%)
Heart Rate Irregular
9 (.3%)
Joint Swelling
9 (.3%)
Toxic Anterior Segment Syndrome
9 (.3%)
Urticaria
9 (.3%)
Diarrhoea
8 (.26%)
Drug Interaction
8 (.26%)
Dysgeusia
8 (.26%)
Inappropriate Schedule Of Drug Admi...
8 (.26%)
Nausea
8 (.26%)
Syncope
8 (.26%)
Tinnitus
8 (.26%)
Blindness Transient
7 (.23%)
Decreased Appetite
7 (.23%)
Depressed Level Of Consciousness
7 (.23%)
Disorientation
7 (.23%)
Eyelid Disorder
7 (.23%)
Eyelid Exfoliation
7 (.23%)
Fall
7 (.23%)
Feeling Abnormal
7 (.23%)
Sinus Disorder
7 (.23%)
Skin Discolouration
7 (.23%)
Throat Tightness
7 (.23%)
Weight Decreased
7 (.23%)
Arrhythmia
6 (.2%)
Atrial Fibrillation
6 (.2%)
Epistaxis
6 (.2%)
Influenza
6 (.2%)
Ocular Hypertension
6 (.2%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Combigan, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Combigan is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Combigan

What are the most common Combigan adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Combigan, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Combigan is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Combigan According to Those Reporting Adverse Events

Why are people taking Combigan, according to those reporting adverse events to the FDA?

Glaucoma
798
Drug Use For Unknown Indication
147
Intraocular Pressure Increased
111
Product Used For Unknown Indication
100
Open Angle Glaucoma
30
Ocular Hypertension
28
Show More Show More
Intraocular Pressure Test
18
Cataract Operation
11
Eye Disorder
10
Eye Operation
8
Cataract
6
Prophylaxis
6
Developmental Glaucoma
6
Postoperative Care
6
Borderline Glaucoma
5
Retinal Disorder
4
Retinopathy
4
Abnormal Sensation In Eye
4
Pigmentary Glaucoma
3
Uveitis
3
Intraocular Pressure Test Abnormal
3
Optic Ischaemic Neuropathy
3
Anterior Chamber Disorder
3
Angle Closure Glaucoma
3
Scleritis
3
Accidental Exposure
2
Retinal Detachment
2
Pain
2
Eye Inflammation
2
Gout
2
Dry Eye
2
Normal Tension Glaucoma
2
Papilloedema
1
Eye Injury
1
Optic Nerve Disorder
1
Retinitis
1
Macular Degeneration
1
Endophthalmitis
1
Optic Neuropathy
1
Off Label Use
1
Swollen Tongue
1
Venous Thrombosis
1
Retinal Vein Occlusion
1
Corneal Dystrophy
1
Hypertension
1
Maternal Exposure Timing Unspecifie...
1
Arthritis
1
Eye Infection
1
Transplant
1
Medical Observation
1
Ocular Neoplasm
1

Drug Labels

LabelLabelerEffective
CombiganPhysicians Total Care, Inc.15-APR-11
CombiganAllergan, Inc.12-OCT-12

Combigan Case Reports

What Combigan safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Combigan. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Combigan.